Background: Publishing separate, yet very similar pieces of a single dataset across multiple papers is known as ‘salami slicing’. This practice may be motivated by researchers wishing to increase their publication counts and by the desire to increase exposure of their findings. ‘Salami slicing’ may also be used by the drug industry to help widely disseminate positive findings regarding its products. Journal editors across many scientific disciplines have bemoaned such duplicative publications on several occasions. However, little research has been conducted on the frequency of such publication practices, and findings have been inconsistent. No research has investigated whether ‘salami slicing’ may also occur in publications presenting results from pooled analyses of clinical trials. Methods: We examined the scientific literature on duloxetine as a treatment for depression, examining how data from clinical trials were reported across 43 pooled analyses. Results: The vast majority of pooled analyses (88%) had at least one author who was employed by the manufacturer of duloxetine. Several pooled analyses based on highly overlapping clinical trials presented efficacy and safety data that did not answer unique research questions, and thus appeared to qualify as salami publications. Six clinical trials had their data utilized as part of 20 or more separately published pooled analyses. Conclusions: Such redundant publications add little to scientific understanding and represent a poor use of peer reviewer and editorial resources.

Keywords:
Duloxetine, Salami slicing, duplicate publication, Depression, Pooled analysis
1.
Brochard L, Brun-Buisson C: Salami publication: a frequent practice affecting readers’ confidence. Intensive Care Med 2007;33:212–213.
2.
Hoit JD: Salami science. Am J Speech Lang Pathol 2007;16:94.
3.
Johnson C: Repetitive, duplicate, and redundant publications: a review for authors and readers. J Manipulative Physiol Ther 2006;29:505–509.
4.
Baggs JG: Issues and rules for authors concerning authorship versus acknowledgements, dual publication, self plagiarism, and salami publishing. Res Nurs Health 2008;31:295–297.
5.
Britton J, Knox AJ: Duplicate publication, redundant publication, and disclosure of closely related publications. Thorax 1999;54:378.
6.
Norman I, Griffiths P: Duplicate publication and ‘salami slicing’: ethical issues and practical solutions. Int J Nurs Stud 2008;45:1257–1260.
7.
Moffatt B, Elliott C: Ghost marketing: pharmaceutical companies and ghostwritten journal articles. Perspect Biol Med 2007;50:18–31.
8.
Eli Lilly: 2001 integrated product plan: Zyprexa product team. http://www.furiousseasons.com/zyprexa%20documents/ZY201249534.pdf.
9.
PeerView, Inc: About PeerView, Inc. 2005. http://epeerview.com/general/about.html.
10.
Villarroel EP: Master plan: the making of a successful publication strategy. Pharmavoice 2007;3:1–5.
11.
Bailey BJ: Duplicate publication in the field of otolaryngology-head and neck surgery. Otolaryngol Head Neck Surg 2002;126:211–216.
12.
Durani P: Duplicate publications: redundancy in plastic surgery literature. J Plast Reconstr Aesthet Surg 2006;59:975–977.
13.
Schein M, Paladugu R: Redundant surgical publications: tip of the iceberg? Surgery 2001;129:655–661.
14.
von Elm E, Poglia G, Walder B, Tramèr MR: Different patterns of duplicate publication: an analysis of articles used in systematic reviews. JAMA 2004;291:974–980.
15.
Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B: Evidence b(i)ased medicine – Selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003;326:1171–1173.
16.
Spielmans GI: Duloxetine does not relieve painful physical symptoms in depression: a meta-analysis. Psychother Psychosom 2008;77:12–16.
17.
Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS: Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005;143:415–426.
18.
Wohlreich MM, Mallinckrodt CH, Watkin JG, Wilson MG, Greist JH, Delgado PL, Fava M: Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine. Ann Clin Psychiatry 2005;17:259–268.
19.
Wohlreich MM, Martinez JM, Mallinckrodt CH, Prakash A, Watkin JG, Fava M: An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. J Clin Psychopharmacol 2005;25:552–560.
20.
Bailey RK, Mallinckrodt CH, Wohlreich MM, Watkin JG, Plewes JM: Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy. J Natl Med Assoc 2006;98:437–447.
21.
Lewis-Fernández R, Blanco C, Mallinckrodt CH, Wohlreich MM, Watkin JG, Plewes JM: Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in US Hispanic and majority Caucasian patients. J Clin Psychiatry 2006;67:1379–1390.
22.
Stewart DE, Wohlreich MM, Mallinckrodt CH, Watkin JG, Kornstein SG: Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients. J Affect Disord 2006;94:183–189.
23.
Kornstein SG, Wohlreich MM, Mallinckrodt CH, Watkin JG, Stewart DE: Duloxetine efficacy for major depressive disorder in male versus female patients: data from 7 randomized, double-blind, placebo-controlled trials. J Clin Psychiatry 2006;67:761–770.
24.
Thase ME, Tran PV, Wiltse C, Pangallo BA, Mallinckrodt C, Detke MJ: Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol 2005;25:132–140.
25.
Wernicke J, Lledó A, Raskin J, Kajdasz DK, Wang F: An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 2007;30:437–455.
26.
Wise TN, Perahia DG, Pangallo BA, Losin WG, Wiltse CG: Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim Care Companion J Clin Psychiatry 2006;8:269–278.
27.
Acharya N, Rosen AS, Polzer JP, D’Souza DN, Perahia DG, Cavazzoni PA, Baldessarini RJ: Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol 2006;26:587–594.
28.
Perahia DG, Kajdasz DK, Desaiah D, Haddad PM: Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord 2005;89:207–212.
29.
Dunner DL, D’Souza DN, Kajdasz DK, Detke MJ, Russell JM: Is treatment-associated hypomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depression. J Affect Disord 2005;87:115–119.
30.
Delgado PL, Brannan SK, Mallinckrodt CH, Tran PV, McNamara RK, Wang F, Watkin JG, Detke MJ: Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005;66:686–692.
31.
Viktrup L, Pangallo BA, Detke MJ, Zinner NR: Urinary side effects of duloxetine in the treatment of depression and stress urinary incontinence. Prim Care Companion J Clin Psychiatry 2004;6:65–73.
32.
Greist J, McNamara RK, Mallinckrodt CH, Rayamajhi JN, Raskin J: Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin Ther 2004;26:1446–1455.
33.
Nelson JC, Wohlreich MM, Mallinckrodt CH, Detke MJ, Watkin JG, Watkin JG, Kennedy JS: Duloxetine for the treatment of major depressive disorder in older patients. Am J Geriatr Psychiatry 2005;13:227–235.
34.
Burt VK, Wohlreich MM, Mallinckrodt CH, Detke MJ, Watkin JG, Stewart DE: Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years. Psychosomatics 2005;46:345–354.
35.
Bech P, Kajdasz DK, Porsdal V: Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology (Berl) 2006;188:273–280.
36.
Pritchett YL, Marciniak MD, Corey-Lisle PK, Berzon RA, Desaiah D, Detke MJ: Use of effect size to determine optimal dose of duloxetine in major depressive disorder. J Psychiatr Res 2007;41:311–318.
37.
Mallinckrodt CH, Prakash A, Andorn AC, Watkin JG, Wohlreich MM: Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res 2006;40:337–348.
38.
Shelton RC, Andorn AC, Mallinckrodt CH, Wohlreich MM, Raskin J, Watkin JG, Detke MJ: Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression. Int Clin Psychopharmacol 2007;22:348–355.
39.
Shelton RC, Prakash A, Mallinckrodt CH, Wohlreich MM, Raskin J, Robinson MJ, Detke MJ: Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Int J Clin Pract 2007;618:1337–1348.
40.
Perahia DG, Kajdasz DK, Royer MG, Walker DJ, Raskin J: Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics. Int Clin Psychopharmacol 2006;21:285–295.
41.
Mallinckrodt CH, Watkin JG, Liu C, Wohlreich MM, Raskin J: Duloxetine in the treatment of major depressive disorder: a comparison of efficacy in patients with and without melancholic features. BMC Psychiatry 2005;5:1.
42.
Perahia DG, Kajdasz DK, Walker DJ, Raskin J, Tylee A: Duloxetine 60 mg once daily in the treatment of milder major depressive disorder. Int J Clin Pract 2006;60:613–620.
43.
Cookson J, Gilaberte I, Desaiah D, Kajdasz DK: Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat. Int Clin Psychopharmacol 2006;21:267–273.
44.
Hirschfeld RM, Mallinckrodt C, Lee TC, Detke MJ: Time course of depression-symptom improvement during treatment with duloxetine. Depress Anxiety 2005;21:170–177.
45.
Brannan SK, Mallinckrodt CH, Detke MJ, Watkin JG, Tollefson GD: Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies. J Psychiatr Res 2005;39:161–172.
46.
Dunner DL, Goldstein DJ, Mallinckrodt C, Lu Y, Detke MJ: Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety 2003;18:53–61.
47.
Beebe FA: Publication planning. Med Mark Media 2004;39:40–46.
48.
Fava GA: The decline of pharmaceutical psychiatry and the increasing role of psychological medicine. Psychother Psychosom 2009;78:220–227.
49.
Jureidini JN, McHenry LB: Key opinion leaders and paediatric antidepressant overprescribing. Psychother Psychosom 2009;78:197–201.
50.
Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA: Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389–399.
51.
Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA: Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383–390.
52.
Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF: Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005;39:43–53.
53.
Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA: Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308–315.
54.
Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA: Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63:225–231.
55.
Ballesteros J, Callado LF, Gutierrez M: An independent meta-analysis using summary data for clinical response, remission, and discontinuation for any reason from the 6 pivotal phase III randomized clinical trials of duloxetine in major depressive disorder. J Clin Psychopharmacol 2007;27:219–221.
56.
Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ: Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry 2006;21:367–378.
57.
Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I: Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457–470.
58.
Wise TN, Wiltse CG, Iosifescu DV, Sheridan M, Xu JY, Raskin J: The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity. Int J Clin Pract 2007;61:1283–1293.
59.
Eckert L, Lançon C: Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons. BMC Psychiatry 2006;6:30.
60.
Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM: The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 2004;65:521–530.
61.
Fava M, Martinez JM, Greist J, Marangell LB, Brown E, Chen L, Wohlreich MM: The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study. Ann Clin Psychiatry 2007;19:187–195.
62.
Gahimer J, Wernicke J, Yalcin I, Ossanna MJ, Wulster-Radcliffe M, Viktrup L: A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin 2007;23:175–184.
63.
Goldstein DJ, Lu Y, Detke MJ, Hudson J, Iyengar S, Demitrack MA: Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004;45:17–28.
64.
Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV: Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol 2005;20:327–341.
65.
Khan A, Schwartz K: Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials: analysis of the FDA summary basis of approval reports. Ann Clin Psychiatry 2007;19:31–36.
66.
Mallinckrodt CH, Goldstein DJ, Detke MJ, Lu Y, Watkin JG, Tran PV: Duloxetine: a new treatment for the emotional and physical symptoms of depression. Prim Care Companion J Clin Psychiatry 2003;5:19–28.
67.
Mallinckrodt CH, Raskin J, Wohlreich MM, Watkin JG, Detke MJ: The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials. BMC Psychiatry 2004;4:26.
68.
Mallinckrodt CH, Meyers AL, Prakash A, Faries DE, Detke MJ: Simple options for improving signal detection in antidepressant clinical trials. Psychopharmacol Bull 2007;40:101–114.
69.
Raskin J, Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ, Rotz BT, Mohs RC: Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007;164:900–909.
70.
Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM: Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr Med Res Opin 2007;23:1303–1318.
71.
Nelson C, Pritchett YL, Martynov O, Yu JY, Mallinckrodt CH, Detke MJ: The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim Care Companion J Clin Psychiatry 2006;8:212–219.
72.
Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME: A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res 2008;42:22–34.
73.
Raskin J, Xu JY, Kajdasz DK: Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder. Int Psychogeriatr 2008;20:309–327.
74.
Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, Wohlreich MM: Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 2007;23:401–416.
75.
Papakostas GI, Worthington JJ, Iosifescu DV, Kinrys G, Burns AM, Fisher LB, Homberger CH, Mischoulon D, Fava M: The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety 2006;23:178–181.
76.
van Baardewijk M, Vis PM, Einarson TR: Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder. Curr Med Res Opin 2005;21:1271–1279.
77.
Vis PM, van Baardewijk M, Einarson TR: Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. Ann Pharmacother 2005;39:1798–1807.
78.
Perahia DG, Gilaberte I, Wang F, Wiltse CG, Huckins SA, Clemens JW, Montgomery SA, Montejo AL, Detke MJ: Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br J Psychiatry 2006;188:346–353.
79.
Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB: Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003;64:1237–1244.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.